A Mutual Recognition Agreement for Pharma GMP Inspections

by | Aug 12, 2019 | EMA, EU, FDA, GMP, Regulatory

The European Medicines Agency (EMA) and the United States FDA have fully implemented the Mutual Recognition Agreement beginning July 11, 2019. This agreement allows the European member states and the FDA to rely on each other’s GMP inspections of pharmaceutical manufacturers.1

In June 2017, the EU commission confirmed that the US FDA has the capability to carry out GMP inspections at a level equivalent to the European Union. The FDA confirmed the capability of the following EU member states to carry out GMP inspections equivalent to the level of FDA:2

Austria, Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Hungary, Romania, Ireland, Lithuania, Portugal, Belgium, Denmark, Finland, Latvia, Estonia, Poland, Slovenia, Bulgaria, Cyprus, Luxembourg, Netherlands, Germany and Slovakia which as confirmed on 11th July 2019.

The mutual recognition agreement will help reduce redundancies in GMP inspections. In other words, the EU member states will not duplicate inspections conducted by the FDA and Vice a Versa. However, both have the right to conduct inspections in each other’s territories at any time. 2

Under this MRA, pharmaceutical companies can stop import testing of their products provided that the product was manufactured in the US with proper controls. However, each batch/lot should be accompanied by a batch certificate (in alignment with the WHO certification scheme on the quality of medicinal products) issued by the manufacturer certifying that the product complies with requirements of the marketing authorization and signed by the person responsible for releasing the batch/lot.2

Currently, the products that are covered under this MRA are:

  • Marketed finished pharmaceuticals for human use in various pharmaceutical dosage forms such as tablets, capsules, ointments, and injectables, including:
    • Medical gases;
    • Radiopharmaceuticals or radioactive biological products;
    • Herbal (botanical) products if classified as medicinal products;
    • Homeopathic products.
  • Marketed biological products:
    • Therapeutic biotechnology-derived biological products;
    • Allergenic products.
  • Intermediates
  • Active pharmaceutical ingredients or bulk drug substance.

Veterinary products, human vaccines, and plasma-derived products are not included within the scope of this agreement, but their inclusion will be considered in the coming years. This MRA is currently under full implementation and new product categories will be considered to be added to the scope of this MRA.2 We will keep you posted on all new updates in this space.

In the meantime, if you need help with your GMP compliance, contact us at 248-987-4497 or email us at info@emmainternational.com.


1RAPS (July 2019) US and EU Fully Implement Mutual Agreement on GMP Inspections retrieved on 08/07/2019 from https://www.raps.org/news-and-articles/news-articles/2019/7/us-and-eu-fully-implement-mutual-agreement-on-gmp?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=Focus%20on%20Pharma:%20July%20(copys

2European Medicines Agency (July 2019) Questions & Answers on the impact of Mutual Recognition Agreement between the European Union and the United States as of 11 July 2019 retrieved on 08/07/2019 from https://www.ema.europa.eu/en/documents/other/questions-answers-impact-mutual-recognition-agreement-between-european-union-united-states-11-july_en.pdf

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This